{"id":7105,"date":"2025-05-22T14:00:33","date_gmt":"2025-05-22T11:00:33","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7105"},"modified":"2025-05-22T14:01:19","modified_gmt":"2025-05-22T11:01:19","slug":"risk-scores-tools-for-predicting-cardiovascular-risk-in-asymptomatic-individuals","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/risk-scores-tools-for-predicting-cardiovascular-risk-in-asymptomatic-individuals\/","title":{"rendered":"Risk Scores &#038; Tools for Predicting Cardiovascular Risk in Asymptomatic Individuals"},"content":{"rendered":"<p>Risk Scores &amp; Tools for Predicting Cardiovascular Risk in Asymptomatic Individuals ;<br \/>\nThese tools are designed to estimate the future risk of cardiovascular events\u2014such as myocardial infarction or stroke\u2014over a specific period (usually 10 years or lifetime). They are preventive in nature and do not require symptoms. Based on clinical and\/or imaging markers, they support decision-making in lifestyle changes and primary prevention strategies (e.g., statins).<br \/>\nHere is a summary of the most relevant and widely used risk assessment tools in asymptomatic individuals:<\/p>\n<p>1. SCORE2 \/ SCORE2-OP (Europe \u2013 ESC)<br \/>\n\u2022 Target: Adults aged 40\u201369 (SCORE2), and \u226570 (SCORE2-OP)<br \/>\n\u2022 Purpose: 10-year risk of first fatal and non-fatal CVD event<br \/>\n\u2022 Ideal for: General European population<br \/>\n\u2022 Link:<br \/>\nhttps:\/\/www.escardio.org\/Education\/ESC-Scientific-Document-Library\/SCORE2-new-CVD-risk-assessment-in-Europe<\/p>\n<p>2. ASCVD Risk Estimator Plus (USA \u2013 ACC\/AHA)<br \/>\n\u2022 Target: Adults aged 40\u201379 without known ASCVD<br \/>\n\u2022 Purpose: Estimates both 10-year and lifetime ASCVD risk<br \/>\n\u2022 Link:<br \/>\n<a href=\"https:\/\/tools.acc.org\/ASCVD-Risk-Estimator-Plus\">https:\/\/tools.acc.org\/ASCVD-Risk-Estimator-Plus<\/a><\/p>\n<p>3. QRISK3 (UK \u2013 NHS)<br \/>\n\u2022 Target: Adults aged 25\u201384 without CVD<br \/>\n\u2022 Purpose: 10-year risk of MI or stroke<br \/>\n\u2022 Link:<br \/>\n<a href=\"https:\/\/www.qrisk.org\/three\/\">https:\/\/www.qrisk.org\/three\/<\/a><\/p>\n<p>4. Framingham Risk Score (USA \u2013 NHLBI)<br \/>\n\u2022 Target: Adults aged 30\u201374 without prior CVD<br \/>\n\u2022 Purpose: 10-year CHD\/CVD risk estimate<br \/>\n\u2022 Link:<br \/>\n<a href=\"https:\/\/www.mdcalc.com\/calc\/61\/framingham-risk-score-hard-coronary-heart-disease\">https:\/\/www.mdcalc.com\/calc\/61\/framingham-risk-score-hard-coronary-heart-disease<\/a><\/p>\n<p>5. Reynolds Risk Score (USA \u2013 Harvard)<br \/>\n\u2022 Target: Men \u226550, Women \u226545, healthy individuals<br \/>\n\u2022 Purpose: 10-year CVD risk (adds hs-CRP &amp; family history)<br \/>\n\u2022 Link:<br \/>\n<a href=\"https:\/\/www.reynoldsriskscore.org\/\">https:\/\/www.reynoldsriskscore.org\/<\/a><\/p>\n<p>6. MESA Risk Score (USA \u2013 MESA Study)<br \/>\n\u2022 Target: Asymptomatic adults with intermediate risk<br \/>\n\u2022 Purpose: 10-year CHD risk (includes CAC score)<br \/>\n\u2022 Link:<br \/>\n<a href=\"https:\/\/www.mesanhlbi.org\/MESACHDRisk\/MesaRiskScore\/RiskScore.aspx\">https:\/\/www.mesanhlbi.org\/MESACHDRisk\/MesaRiskScore\/RiskScore.aspx<\/a><\/p>\n<p>7. CAC Score (Agatston Score)<br \/>\n\u2022 Type: Imaging-based only (coronary CT)<br \/>\n\u2022 Use: Stratify statin decisions based on CAC value<br \/>\n\u2022 Endorsed by: 2018 AHA\/ACC and 2021 AHA<br \/>\n\u2022 Link:<br \/>\n<a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000946\">https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000946<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Risk Scores &amp; Tools for Predicting Cardiovascular Risk in Asymptomatic Individuals ; These tools are designed to estimate the future risk of cardiovascular events\u2014such as myocardial infarction or stroke\u2014over a specific period (usually 10 years or lifetime). They are preventive in nature and do not require symptoms. Based on clinical and\/or imaging markers, they support [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7105","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7105","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7105"}],"version-history":[{"count":2,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7105\/revisions"}],"predecessor-version":[{"id":7108,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7105\/revisions\/7108"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7105"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7105"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7105"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}